VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Shannon Puhalla on PALOMA-3 Updates

Shannon Puhalla, MD
Published: Thursday, Aug 13, 2015



Shannon Puhalla, MD, assistant professor of Medicine, University of Pittsburgh, discusses recent updates of the PALOMA3- trial.

PALOMA-3 was a phase III trial of targeted drug palbociclib in combination with hormone therapy fulvestrant in women with relapsed, metastatic hormone receptor-positive, HER2-negative breast cancer.

The study found a 6-month improvement in progression-free survival (PFS) with palbociclib. There were high rate of neutropenia with palbociclib compared to fulvestrant alone.



Shannon Puhalla, MD, assistant professor of Medicine, University of Pittsburgh, discusses recent updates of the PALOMA3- trial.

PALOMA-3 was a phase III trial of targeted drug palbociclib in combination with hormone therapy fulvestrant in women with relapsed, metastatic hormone receptor-positive, HER2-negative breast cancer.

The study found a 6-month improvement in progression-free survival (PFS) with palbociclib. There were high rate of neutropenia with palbociclib compared to fulvestrant alone.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x